Biotech's Sweet Spot

Interested in big profits? Check this out... [Shield] AN OXFORD CLUB PUBLICATION [Liberty Through Wealth]( [View in browser]( SPONSORED ["THIS is Where AI Will Have the Biggest Economic Impact... And Where Early Investors Can Make a Killing." - Marc Lichtenfeld]( There's a corner of the AI market set to explode... that investors are completely missing. But not everyone is... The CEO of Nvidia said, that this will be "the next amazing revolution... It will be one of the biggest ever." And the company is putting its money where its mouth is - investing just ahead of a big catalyst that could thrust this opportunity into the spotlight. [On June 27 at 2 p.m. ET]( Marc Lichtenfeld is blowing the lid off of this breaking story - he'll give details about where exactly Nvidia is investing... how you could follow them... why Time Magazine says this revolution is coming faster than we expect... and he'll be making his biggest and boldest prediction yet. [GO HERE to claim a free spot to this exclusive event.]( EDITOR'S NOTE Chief Income Strategist Marc Lichtenfeld's readers know he's a big fan of investing in the biotech sector. In fact, he's one of the most knowledgeable biotech experts you'll find anywhere! So today, I've invited him to share some of his best tips for identifying [biotech stocks with the potential to soar](. Marc will also be hosting a free live event this Thursday, June 27, at 2 p.m. ET to discuss an [urgent situation regarding a tiny biotech stock](. He wants to get the word out to as many people as possible. [Reserve your spot here.]( - Nicole Labra, Senior Managing Editor THE SHORTEST WAY TO A RICH LIFE [The Sweet Spot to Invest in the Biotech Sector]( [Marc Lichtenfeld, Chief Income Strategist, The Oxford Club]( [Marc Lichtenfeld]( The biotech sector tends to attract investors who are interested in exciting new medical advances and drawn to big profits. There are lots of ways to invest in the sector. Some investors prefer the comfort of big profitable biotechs that have various product offerings and deep pipelines, like Gilead Sciences (Nasdaq: GILD). Others would rather take a chance on a small biotech stock that could be a home run. Either way, there's no sector that moves as much or as quickly as biotech. Consider Five Prime Therapeutics. In November 2020, the stock was trading at around $5... but then it jumped 349% in one day thanks to positive Phase 2 data for its cancer drug bemarituzumab. Then, just a few months later, the stock spiked another 78% in one day on news it was being acquired by Amgen. All in all, Five Prime soared 605% in less than five months. [Insight five prime]( Five Prime is a perfect illustration of why Phase 2 clinical trials are my sweet spot in the biotech sector. SPONSORED [JOLTS Trade LIVE Tuesday, June 25 at 2 pm]( [Secret Loophole]( When The Gov't Drops Economic Reports... This One Trade Could Have Made 253%... 327%... Even 383% gains... Enough for overnight payouts of $25,300... $32,700... heck even $38,300! [Discover The JOLTS Loophole (BEFORE Tues at 2 pm!)]( In case you aren't familiar with them, here's a brief rundown of the various phases of clinical trials: - Phase 1: A small trial of healthy volunteers. The drug is studied to understand how it works in the human body. (Cancer drugs are an exception in that they are not given to healthy volunteers because they are typically too toxic. Instead, they are given to cancer patients.) - Phase 2: A midsized trial with more patients. Safety and efficacy are analyzed. - Phase 3: A large trial where an optimal dose is studied for safety and efficacy. The data from this trial is what is submitted to regulatory agencies for approval. You'd be shocked by how many people are involved in the clinical trial process. Certainly, brilliant scientists create the drugs and vaccines, but it takes an army of people to develop and market a successful drug - from the doctors overseeing the trial to the phlebotomists drawing blood to the nurses examining the volunteers to the case managers keeping careful track of records to the other staff making sure patients have all of the information they need. And that's just in Phase 2. There's a lot more work that needs to be done after Phase 2 before the drug crosses the finish line and gets to market. But data from Phase 2 trials is usually the first real indication that a drug may be safe and effective. Now, not all drugs cross the finish line. Roughly half of all drugs with a successful Phase 2 trial fail in Phase 3. But Phase 2 is the first time you can realistically begin to think the company may have something worthwhile. For that reason, stocks can spike on strong Phase 2 data, especially smaller stocks. And early investors in the company will often sell some of their positions so as not to risk a failure in Phase 3. So when investing in biotech, I like to find small cap and midcap stocks with upcoming Phase 2 data that can act as a big catalyst for a price move. That gives me the best chance of getting in before a big jump in the near future. Good investing, Marc P.S. An innovative (and little-known) biotech company recently [caught my eye](. It's using artificial intelligence in a unique way that could revolutionize industries worth trillions of dollars... it's partnered with AI and tech powerhouse Nvidia... and it has an [upcoming catalyst]( that could cause the stock to go NUCLEAR. I'll be sharing more details about this situation in a free live broadcast this Thursday, June 27, at 2 p.m. ET. It's 100% free to attend - [go here to claim your spot at the event!]( [Leave a Comment]( [OXF Seven]( BUILD AND PROTECT YOUR WEALTH - [How to Profit From the Surge (Outside the Stock Market)... Click Here.]( - [Nvidia Bounces Back...]( - [This FREE Package Reveals Stocks That Pay You CASH]( - [Big Mover, Alnylam...]( JOIN THE CONVERSATION [Facebook]( [Facebook]( [LinkedIn logo]( [LinkedIn]( [Email Share](mailto:?subject=A%20great%20piece%20from%20Liberty%20Through%20Wealth...&body=From%20Liberty%20Through%20Wealth:%0D%0A%0DInterested%20in%20big%20profits?%20Check%20this%20out...%0A%0D [Email Share](mailto:?subject=A%20great%20piece%20from%20Liberty%20Through%20Wealth...&body=From%20Liberty%20Through%20Wealth:%0D%0A%0DInterested%20in%20big%20profits?%20Check%20this%20out...%0A%0D MORE FROM LIBERTY THROUGH WEALTH [Token Offerings]( [How Shareholders - Like You - are Public Benefactors]( [Token Offerings]( [This Father’s Biggest Wish]( [Token Offerings]( [The Key to Finding Winners in the AI Craze]( [Token Offerings]( [Steer Clear of This Investment]( SPONSORED [DIVIDENDS: No. 1 Way to Collect Passive Income]( If you want to get rich, passive income is the name of the game. Real estate is risky. "Side hustles" take work. But [dividend stocks are truly 100% passive!]( And while they might sound old-fashioned... They are the single best way to grab MORE INCOME - while you eat, sleep and vacation - month after month. Getting started couldn't be easier! To prove it, I'm giving you the Ultimate Dividend Package (FREE OF CHARGE). [Click here to get it for free.]( [The Oxford Club]( You are receiving this email because you subscribed to Liberty Through Wealth. Liberty Through Wealth is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Liberty Through Wealth]( | [Unsubscribe]( © 2024 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [877.806.4508](#) | International: [+1.443.353.4610](#) [Oxfordclub.com]( Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.